GLP-1 receptor agonists, commonly prescribed for type 2 diabetes and weight management, are attracting attention for another potential benefit. New research presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting suggests these medications may help reduce the risk of cancer progression in several obesity-related cancers.
The study analyzed real-world health data from more than 12,000 patients worldwide and found that individuals taking GLP-1 receptor agonists were significantly less likely to develop metastatic disease compared with patients taking another class of diabetes medications known as DPP-4 inhibitors.
While further research is needed before any changes to cancer treatment guidelines can be considered, the findings offer a promising new area of investigation for cancer prevention and supportive oncology.
GLP-1 receptor agonists, often referred to as GLP-1 drugs, are medications used to improve blood sugar control and support weight loss. Popular examples include semaglutide, tirzepatide, liraglutide, dulaglutide, and lixisenatide.
These drugs work by mimicking a naturally occurring hormone called glucagon-like peptide-1. This hormone helps regulate insulin production, reduce appetite, slow stomach emptying, and improve metabolic health.
Researchers have long suspected that GLP-1 medications may have benefits beyond diabetes management. Their anti-inflammatory and immune-modulating effects have raised questions about whether they could also influence cancer development and progression.
People with diabetes face a higher risk of developing several forms of cancer compared with those without the condition. According to researchers, chronic inflammation, elevated insulin levels, and persistent high blood sugar create an environment that may encourage cancer growth.
Estimates suggest that approximately 29 to 40 million Americans live with diabetes. As a result, understanding how diabetes treatments affect cancer outcomes has become an important area of medical research.
Previous studies have indicated that GLP-1 medications may help lower the risk of developing certain obesity-related cancers, particularly colorectal cancer. However, less was known about whether these drugs could impact cancer progression in patients who already have a diagnosis.
The research team evaluated data from the TriNetX database, which contains health information from medical institutions around the world.
The study included 12,112 individuals diagnosed with stage I, II, or III cancer. Researchers focused on seven obesity-related cancers:
Half of the participants began treatment with a GLP-1 receptor agonist after their cancer diagnosis. The other half received DPP-4 inhibitors, also known as gliptins.
Researchers compared the rates at which patients in each group progressed to stage IV metastatic cancer.
The results revealed a notable reduction in metastatic progression among patients using GLP-1 medications in four major cancer types.
Patients taking GLP-1 drugs experienced significantly lower rates of metastasis.
This represented roughly a 50% reduction in metastatic progression risk.
Breast cancer patients also showed meaningful improvements.
Researchers observed a substantial decrease in the likelihood of progression to stage IV disease.
For colorectal cancer, metastasis rates were:
These findings align with earlier research suggesting protective effects against colorectal cancer development.
Patients with liver cancer demonstrated another encouraging trend.
Across these four cancer types, GLP-1 users were approximately 38% to 50% less likely to develop metastatic disease compared with those taking gliptins.
The study also examined prostate, pancreatic, and kidney cancers.
Although patients taking GLP-1 medications generally experienced fewer metastatic events than those using gliptins, the differences did not reach statistical significance.
Researchers caution that this does not necessarily mean the medications are ineffective in these cancers. Larger studies may be needed to determine whether a true benefit exists.
Beyond medication use, investigators explored whether GLP-1 receptor expression within tumors might influence patient outcomes.
Using data from The Cancer Genome Atlas, researchers evaluated tumor GLP-1 receptor levels across the seven cancer types.
The analysis revealed that patients with higher GLP-1 receptor expression experienced:
These findings suggest that GLP-1 signaling pathways may play a meaningful role in tumor biology and cancer progression.
If future studies confirm this relationship, it could help explain why GLP-1 medications appear to provide benefits beyond blood sugar control.
One concern surrounding GLP-1 medications involves reports of gastrointestinal side effects and inflammation of the pancreas.
In this study, researchers found that adverse event rates were similar between the GLP-1 and gliptin groups.
Importantly, instances of stomach inflammation and pancreatic inflammation were not higher among patients taking GLP-1 drugs.
While ongoing monitoring remains important, these results provide additional reassurance regarding the safety profile of these medications in cancer patients.
Metastatic cancer remains one of the most challenging aspects of cancer treatment. Once cancer spreads to distant organs, treatment becomes more complex and survival rates often decline.
If GLP-1 medications can help delay or reduce metastatic progression, they may eventually become an important supportive therapy for patients with both diabetes and cancer.
The findings are particularly relevant given the increasing popularity of GLP-1 drugs worldwide. Millions of people currently use medications such as semaglutide and tirzepatide for diabetes management and weight loss.
Understanding how these therapies influence cancer outcomes could have significant implications for public health and oncology care.
According to supportive oncology expert Dr. Marcin Chwistek of Fox Chase Cancer Center, GLP-1 receptor agonists have always shown potential beyond glucose control because of their anti-inflammatory and immune-regulating properties.
He noted that what makes the new findings particularly noteworthy is the consistency observed across multiple cancer types and the large volume of patient data analyzed.
Experts believe the evidence is strong enough to justify future randomized controlled trials.
Researchers are now focused on understanding exactly how GLP-1 medications may influence cancer progression.
Several possible mechanisms are being investigated:
Future randomized clinical trials will be necessary to establish whether GLP-1 medications directly reduce cancer progression and improve survival outcomes.
Such studies would provide stronger evidence than observational data alone and could potentially influence future cancer treatment strategies.
The latest research presented at the 2026 ASCO Annual Meeting adds to growing evidence that GLP-1 receptor agonists may offer benefits far beyond diabetes and weight management.
Among patients with lung, breast, colorectal, and liver cancer, GLP-1 medications were associated with substantially lower rates of progression to metastatic disease. Researchers also found links between higher tumor GLP-1 receptor expression and improved survival outcomes.
Although these findings are preliminary and do not prove cause and effect, they open an exciting new chapter in cancer research. As clinical trials move forward, scientists hope to determine whether GLP-1 drugs can become part of future strategies aimed at slowing cancer progression and improving patient outcomes.
American Society of Clinical Oncology (ASCO). "GLP-1s May Reduce Metastatic Progression of Certain Obesity-Related Cancers." Presented at the 2026 ASCO Annual Meeting, Chicago, Illinois, May 29 to June 2, 2026.
This article is for informational and educational purposes only and should not be considered medical advice. The findings discussed are based on observational research presented at a scientific meeting and have not yet established a direct cause-and-effect relationship. Patients should consult qualified healthcare professionals before making any decisions regarding cancer treatment, diabetes medications, or weight-loss therapies.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.